



Asparagine restriction enhances CD8⁺ T cell metabolic fitness and antitumoral functionality through an NRF2-dependent stress response

In the format provided by the authors and unedited

Supplementary Information

Methods:

Western blot analysis

Cells were harvested, lysed, and sonicated at 4 °C in a lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% SDS, 5 mM sodium pyrophosphate, protease, and phosphatase inhibitor tablet). Cell lysates were centrifuged at $13,000 \times g$ for 15 min to collect the supernatant. The protein concentrations were determined by the Pierce™ BCA Protein Assay kit. The samples were boiled in NuPAGE® LDS Sample Buffer and Reducing solution for 5 min. The proteins were separated by NuPAGE Protein Gels, transferred to PVDF membranes by the iBlot Gel Transfer Device, then incubated with primary antibodies followed by a corresponding secondary antibody. Immunoblots were developed with LI-COR. Detailed information for primary antibodies and secondary antibodies was provided in Supplementary Table S1.

RNA extraction, qPCR, and RNAseq

Total RNA was isolated using the Quick-RNATM MiniPrep Kit and was reverse transcribed using random hexamer and M-MLV Reverse Transcriptase. BIO-RAD CFX284™ Real-Time PCR Detection System was used for SYBR green-based quantitative PCR. The relative gene expression was determined by the comparative *CT* method, also referred to as the $2^{-\Delta\Delta CT}$ method. The data were presented as the fold change in gene expression normalized to an internal reference gene (beta2-microglobulin) relative to the control (the first sample in the group). Fold change = $2^{-\Delta\Delta C_T}$ = $[(CT_{\text{gene of interest}} - CT_{\text{internal reference}})]_{\text{sample A}} - [(CT_{\text{gene of interest}} - CT_{\text{internal reference}})]_{\text{sample B}}$. Samples for each experimental condition were run in triplicated PCR reactions. Primer sequences were obtained from Primer Bank to detect target genes (Supplementary Table S3).

For RNA sequencing analysis, total RNA was extracted using RNeasy Mini Kit and treated with DNase I according to the manufacturer's instructions. After assessing the quality of total RNA using an Agilent 2100 Bioanalyzer and RNA Nanochip, 150 ng total RNA was treated to deplete ribosomal RNA (rRNA) using target-specific oligos combined with rRNA removal beads. Following rRNA removal, mRNA was fragmented and converted into double-stranded cDNA. Adaptor-ligated cDNA was amplified by limit cycle PCR. After library quality was determined via Agilent 4200 TapeStation and quantified by KAPA qPCR, approximately 60 million paired-

end 150 bp sequence reads were generated on the Illumina HiSeq 4000 platform. Quality control and adapter trimming were accomplished using the FastQC (version 0.11.3) and Trim Galore (version 0.4.0) software packages. Trimmed reads were mapped to the Genome Reference Consortium GRCm38 (mm10) murine genome assembly using TopHat2 (version 2.1.0), and feature counts were generated using HTSeq (version 0.6.1). Statistical analysis for differential expression was performed using the DESeq2 package (version 1.16.1) in R, with the default Benjamini-Hochberg *p-value* adjustment method. The Ingenuity Pathway Analysis (IPA) software, the Gene Set Enrichment Analysis (GSEA) software, and the R Programming Language software were used to analyze gene signature and pathway enrichment.

Supplementary table S1. List of antibodies and cytokines

| Antibodies and recombinant proteins | Vendor | Catalog # | Application |
|---|----------------|------------------|--|
| APC anti-mouse IFN- γ Antibody | BioLegend | 505810 | 1:200 dilution/Flow cytometry |
| PE/Cyanine7 anti-mouse IFN- γ Antibody | BioLegend | 505826 | 1:200 dilution/Flow cytometry |
| APC Anti-mouse TNF- α | BioLegend | 506308 | 1:200 dilution/Flow cytometry |
| APC/Cyanine7 anti-mouse CD8a Antibody | BioLegend | 100714 | 1:300 dilution/Flow cytometry |
| APC anti-mouse TCR β chain Antibody | BioLegend | 109211 | 1:100 dilution/Flow cytometry |
| PE NRF2 rabbit monoclonal Antibody | Cell signaling | 14409 | 1:100 dilution/Flow cytometry |
| APC/Cyanine7 anti-mouse thy1.1 Antibody | BioLegend | 202520 | 1:100 dilution/Flow cytometry |
| Percp anti-mouse thy1.2 Antibody | BioLegend | 140316 | 1:100 dilution/Flow cytometry |
| CD25 Monoclonal Antibody (PC61.5), PE | eBioscience | 12-0251 | 1:300 dilution/Flow cytometry |
| FITC anti-mouse CD8 Antibody | BioLegend | 100705 | 1:200 dilution/Flow cytometry |
| APC/Cyanine7 anti-human CD8a Antibody | BioLegend | 300926 | 1:200 dilution/Flow cytometry |
| PE/Cyanine7 anti-mouse CD4 | BioLegend | 100422 | 1:200 dilution/Flow cytometry |
| PE/Cyanine7 anti-human IFN- γ Antibody | BioLegend | 506518 | 1:200 dilution/Flow cytometry |
| PE anti-human TNF- α Antibody | BioLegend | 502909 | 1:200 dilution/Flow cytometry |
| InVivoMAb anti m PD-L1 | BioXcell | BE0101 | 200 μ g per dose / in vivo immunotherapy |
| InVivoMAb anti m PD-1 | BioXcell | BE0146 | 200 μ g per dose / in vivo immunotherapy |
| InVivoMAb Rat IgG2b Isotype control | BioXcell | BE0090 | 200 μ g per dose / in vivo immunotherapy |
| InVivoMAb anti-mouse CD3 | BioXcell | BE0001 | 2-5 μ g/ml / T cell activation |
| InVivoMAb anti-mouse CD28 | BioXcell | BE0015 | 2-5 μ g/ml / T cell activation |
| Anti-human CD3 (OKT-3) | BioXcell | BE0001 | 1 μ g/ml / PBMCs activation |
| Anti-human CD28 | BioXcell | BE0291 | 1 μ g/ml / PBMCs activation |
| Asparagine synthetase (G-10) | Santa Cruz | sc-365809 | 1:250 / IB |
| anti-actin | Santa Cruz | sc47778 | 1:1000 / IB |

| | | | |
|--|------------------------|--------------|---|
| ATF-4 (D4B8) Rabbit mAb # | Cell Signaling | 11815S | 1:1000 / IB |
| NRF2 (D1Z9C) XP | Cell Signaling | 12721S | 1: 500 / Confocal |
| NRF2 (A 10) | Santa Cruz | 365949 | 1:1000 / IB |
| DAPI | Vector Laboratories | EW-93952-27 | 20 ul/Slide |
| Anti-mouse IgG, HRP-linked Antibody | Cell Signaling | 7076 | 1:3000 / IB |
| Anti-rabbit IgG, HRP-linked Antibody | Cell Signaling | 7074 | 1:3000 / IB |
| Anti-Mouse IgG (H+L), (Alexa Fluor® 647) | Cell Signaling | 4410S | 1:1000 / Confocal |
| Recombinant Murine IL-12 p70 | Peprtech | 210-12 | 5 ng/ml / T cell polarization |
| Recombinant Murine IL-2 | Peprtech | 212-12 H1111 | 5 ng/ml / T cell activation/polarization |

Supplementary table S2. List of cell culture reagents and chemicals


| Cell culture reagents and chemicals | | | |
|--|--------------------------------------|----------------------------|--|
| Name of the chemical/reagent | Vendor | Catalog # | Concentration |
| H-2D(b) human gp100 25-33 peptide | Genescript | RP20344 | 1µM |
| RPMI 1640 Medium Modified w/o L-Glutamine, w/o Amino acids, Glucose (Powder) | US Biologicals | R9010-01 | NA |
| RPMI 1640 Medium | Corning | 10-040-CVR | NA |
| RPMI medium modified w/o asparagine, glutamine, glucose | Gibco | ME18399P1 | NA |
| 2-Mercaptoethanol | Gibco | M6250 | 0.05-0.15mM |
| Cell Stimulation Cocktail (plus protein transport inhibitors) (500X) | eBioscience | 00-4975-93 | 1:500 |
| Lipofectamine 2000 Transfection Reagent | Invitrogen | 11668019 | 8 µl/ml |
| 7-amino-actinomycin D(7AAD) | Biolegend | 420404 | 5 µl/sample |
| D-(+)-Glucose | Sigma-Aldrich | G7021 | 11mM |
| L-Glutamine (¹³ C ₅ , 99%) | Cambridge Isotope Laboratories, Inc. | CLM-1822-H-PK | 4mM |
| MC 228 D-Glucose, [1- ¹⁴ C]- | Moravek Biochemicals | 742-018-0555-A20110726-SBA | 1µCi |
| MT 911 2-Deoxy-D-glucose, [1,2- ³ H(N)]- | Moravek Biochemicals | 257-078-025-A-20130528-TNG | 1µCi |
| MC 1124 L-Glutamine, [¹⁴ C(U)]- | Moravek Biochemicals | 945-012-281-A20170301-SBA | 0.2 µCi |
| Glucose, D-[5- ³ H(N)] | American Radiolabeled Chemicals | 131002 | 1µCi |
| MC 1124 L-Glutamine, [¹⁴ C(U)]- | Moravek Biochemicals | 945-012-281-A20170301-SBA | 1 µCi |
| L-Asparaginase | prospec | ENZ-287 | 10 IU for invivo 0.01IU for invitro |
| L-Asparagine | Sigma | A4159 | 0.3mM |
| FCCP | Sigma | C2520 | 2µM |
| Poly-D-Lysine | Millipore | A3890401 | A3890401 |
| Slide-A-Lyzer Dialysis Cassettes | Thermo Scientific | 87721 | NA |
| Matrigel matrix | Corning | CB40234 | NA |
| Isobutylhydroxylamine hydrochloride | TCI | I0387 | 20 mg/mL |

| | | | |
|--|---|----------------------|----|
| Seahorse XF96 Cell Culture Microplates | Agilent | 101085 | NA |
| E-plates | Agilent | 300600900 | NA |
| Critical commercial assays | Vendor | Catalog # | |
| BrdU kit APC | BioLegend | 370706 | |
| MojoSort™ Mouse CD8 Naïve T Cell Isolation Kit | Biolegend | 480044 | |
| Protein Synthesis Assay Kit | Cayman | 601100 | |
| ELISA MAX™ Deluxe Set Mouse TNF- α - | Biolegend | 430904 | |
| ELISA MAX™ Deluxe Set Mouse IFN- γ | Biolegend | 430804 | |
| Mouse Granzyme B DuoSet ELISA | R & D | DY1865-05 | |
| LEGENDplex™ human CD8/NK panel | Biolegend | 740267 | |
| Seahorse XF- real-time ATP rate assay kit | Agilent | 103592 | |
| Foxp3 / Transcription Factor Staining Buffer Set | e-Bioscience | 00-5523-00 | |
| L-Arginine Assay Kit | Bio vision | K749 | |
| CellTrace™ Violet Cell | Invitrogen | C34557 | |
| carboxyfluorescein diacetate succinimidyl ester (CFSE) | Invitrogen | 65-0850-84 | |
| Pierce™ BCA Protein Assay kit | Thermo fisher scientific | 23227 | |
| M-MLV Reverse Transcriptase | Invitrogen | 28025013 | |
| Rneasy Mini Kit | Qiagen | NC9677589 | |
| Quick-RNATM MiniPrep Kit | Zymo Research | R1055 | |
| MitoTracker™ Green FM | Invitrogen | M7514 | |
| Seahorse XF Media, Supplements & Calibrant | Agilent | 103681 | |
| CellTiter-Glo | Promega | G9241 | |
| Biological samples | | | |
| Buffy coats from healthy human subjects | Central Ohio Region American Red Cross | NA | |
| Experimental models: Organisms/strains | | | |
| WT mouse: C57BL/6NJ, | Jackson Laboratory | Strain #: 000664 | |
| Pmel-1 mouse: B6.Cg- Thy1a/CyTg(TcraTcrb)8Rest/J | Jackson Laboratory | Strain #:005023 | |
| NRF2 KO mouse: B6.129X1-Nfe2l2tm1Ywk/J | Jackson Laboratory | Strain #:017009 | |
| Rag1-/- mouse: B6.129S7-Rag1tm1Mom/J | Jackson Laboratory | Strain #:002216 | |
| WT mouse: B6.PL-Thy1a/CyJ | Jackson Laboratory | Strain #: 000406 | |
| ATF4 KI mouse: B6;129X1- Gt(ROSA)26Sortm2(ATF4)Myz/J | Jackson Laboratory | Strain #:029394 | |
| B-NDG mouse: NOD.CB17-Prkdcscid IL2rgtm1/BcgenHsd | Envigo | NA | |
| ATF4 KO mouse: ATF4fl/fl | Dr. Christopher Adams (Mayo Clinic) | (21) | |
| ASNS KO mouse: C57BL/6N-Asns tm1a(EUCOMM)Wtsi/H) mice | MRC Harwell Institute | Stock code: IVF/5248 | |
| Experimental models: Cell lines | | | |
| B16F10 | American Type Culture Collection | CRL-6475 | |
| LAN-1 | Dr. Xiaotong Song (Baylor College of Medicine) | | |
| B16-gp100 | Dr. Nicholas Restifo (NIH) | (49) | |


| | | |
|--|-------------------------------|-----------|
| CMT167 | Dr. Williams Terence (OSU) | |
| Recombinant DNA | | |
| pCLIP-ALL-EFS-ZsGreen (TELA1013-Negative Control) | Transomic | CAMS 1013 |
| pCLIP-ALL-EFS-ZsGreen (TEVM-1207871-pCLIP-ALL-EFS-ZsGreen) | Transomic | CAMS 1013 |
| pCLIP-ALL-EFS-ZsGreen (TEVM-1140729-pCLIP-ALL-EFS-ZsGreen) | Transomic | CAMS 1013 |
| pCLIP-ALL-EFS-ZsGreen (TEVM-1073587-pCLIP-ALL-EFS-ZsGreen) | Transomic | CAMS 1013 |
| pMIG-Nrf2 Δ Neh2 | This paper | |

Supplementary table S3. List of primers

| qRT-PCR Primers | Forward Primer Sequence (5' → 3') | Reverse Primer Sequence (5' → 3') |
|------------------------|--|--|
| IFN- γ | ATGAACGCTACACACTGCATC | CCATCCTTTTGCCAGTTCCTC |
| TNF- α | GCCCAGGCAGTCAGATCATCT | TTGAGGGTTTGCTACAACATGG |
| Granzyme B | GACCCAGCAGTTTATCCCTGT | CTGGGCCTTGTGCTAGGTA |
| ATF4 | ATGACCGAAATGAGCTTCCTG | GCTGGAGAACCCATGAGGT |
| ASNS | GGAAGACAGCCCCGATTTACT | AGCACGAACTGTTGTAATGTCA |
| Nrf2 | TCAGCGACGGAAAGAGTATGA | CCACTGGTTTCTGACTGGATGT |
| Tubulin | TTCTGGTGCTTGTCTCACTGA | CAGTATGTTCCGGCTTCCCATTC |
| Perforin | AGCACAAGTTCGTGCCAGG | GCGTCTCTCATTAGGGAGTTTTT |
| IL15 | ACATCCATCTCGTGCTACTTGT | GCCTCTGTTTTAGGGAGACCT |
| IL6 | TAGTCCTTCCTACCCCAATTTCC | TTGGTCCTTAGCCACTCCTTC |
| IL2 | GTGCTCCTTGTCAACAGCG | GGGGAGTTTCAGGTTCTGTA |
| IL23 | ATGCTGGATTGCAGAGCAGTA | ACGGGGCACATTATTTTTAGTCT |
| IL4 | GGTCTCAACCCCGAGCTAGT | GCCGATGATCTCTCTCAAGTGAT |
| IL13 | CCTGGCTCTTGCTTGCCCTT | GGTCTTGTGTGATGTTGCTCA |
| IL9 | ATGTTGGTGACATACATCCTTGC | TGACGGTGGATCATCCTTCAG |
| IL22 | ATGAGTTTTTCCCTTATGGGGAC | GCTGGAAGTTGGACACCTCAA |
| IL12 | ATGGCTGCTGCGTTGAGAA | AGCACTCATAGTCTGTCTTGGA |
| T-bet | AGCAAGGACGGCGAATGTT | GTGGACATATAAGCGGTTCCC |
| TCF | CGAAAAGTTCCTCCGGGTTTG | CGTAGCCGGGCTGATTCAT |
| PRDM | TTCTCTTGGAACGCTGTGGG | GGAGCCGGAGCTAGACTTG |
| mouse COI | GCCCCAGATATAGCATTCCC | GTTCATCCTGTTCCCTGCTCC |
| G6PDx | CACAGTGGACGACATCCGAAA | AGCTACATAGGAATTACGGGCAA |
| G6PD2 | AGGTGACCCTAAGCCGGAC | AGGTTTCTTTGGGTAGAAGACCA |
| PGD | ATGGCCAAGCTGACATTG | GCACAGACCACAAATCCATGAT |
| TKT | ATGGAAGTTACCATAAGCCAGA | TGCAGCATGATGTGGGGTG |
| CAD | CTGCCCGGATTGATTGATGTC | GGTATTAGGCATAGCACAAACCA |
| DHODH | TCTTCACCTCTTACCTGACAGC | CATGTTGGAGTCCTGAAACGTA |
| UMPS | GTCACCGAGCTGTATGACGTG | GGTAACGCTGTATAAGGAACTCC |
| CPS1 | CTTCCCACGCTGGAGCAGCC | CCGAAGCACGCCACCTCTCC |
| PPAT | GCGAGGAATGTGGTGTGTTTG | TTTAGGCACTGCACTCCCATC |
| PNP | ATCTGTGGTTCGGCTTAGGA | TGGGGAAAGTTGGGTATCTCAT |
| IMPDH1 | GGCTACGTTCCCGAGGATG | GGCTGATGTCAGGTCCACTT |
| PRPS | ATGCCTAACATCGTGCTCTTC | GATCTCGACACTGGTCTCCTG |
| PFAS | TCTCCTTCATGGGTCTCCCC | AGGCCCTGTTTCTCCTCTATC |
| ADSL | AGCCGCGAGATGTGTTTCTT | TCAATGTTGTTTCAGGTTGACTT |
| ADSS | ACACGGGGTAGAGAATTTGGA | GGTAAGGGCCAACGCAGTA |



Supplemental Figure 1. Gating Strategy for cell proliferation. FSC-SSC-H gating was used as preliminary gating for the lymphocyte population, followed by live cell gating and CFSE.



Supplemental Figure 2. Gating Strategy for analysis of cytokine production. FSC-SSC-H gating was used as preliminary gating for the lymphocyte population, followed by CD8+ staining and intracellular production of IFN- γ and TNF- α .